美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

避孕概念

2,762.58

+23.900.87%

漲家數：3

跌家數：1

平家數：1

市盈率：- -

高：2,764.75

開：2,741.80

低：2,710.01

收：2,738.68

成交量：1,355.25萬

成交額：1.06億

市值：441.42億

流通市值：399.47億

資料載入中...

總覽新聞資訊

Dare Bioscience 宣佈完成600萬美元註冊直接發行，按納斯達克規則市價定價

Dare Bioscience 發布2026年第二季度財報：多產品女性健康戰略推進，商業拐點凸顯

Femasys Inc：Maxim Group 將目標價從30美元下調至10美元，以反映1比20的反向股票分割

Veru Inc. 公布2026財年第三季度財務業績及2B期Plateau臨床試驗進展

特瓦公司試圖向陪審團隱瞞與以色列的關聯，並援引加沙戰爭作為理由

Veru 宣佈關鍵專利獲批：Enobosarm 聯合司美格魯肽用於高質量減重

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4584/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"避孕概念","latestPrice":2762.5803,"timestamp":1786737599999,"preClose":2738.6797,"halted":0,"volume":13552508,"delay":0,"changeRate":0.008727,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":23.900635,"latestTime":"08-14 16:00:00 EDT","open":2741.7964,"high":2764.7478,"low":2710.0066,"amount":105532838.873697,"amplitude":0.019988,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.675768,"peRate":70.141496,"turnoverRate":0.009708,"increases":3,"decrements":1,"flats":1,"marketCap":44142373723.5,"floatMarketCap":39946575171},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2764.7478,"amplitude":0.019988,"preClose":2738.6797,"low":2710.0066,"pbRate":"5.675768","latestPrice":2762.5803,"volume":13552508,"delay":0,"open":2741.7964,"prevYearClose":2379.9924,"prevWeekClose":2664.4,"prevMonthClose":2636.2712,"prevQuarterClose":2562.5076,"fiveDayClose":2664.4,"twentyDayClose":2421.8398,"sixtyDayClose":2533.093,"secType":"PLATE","market":"US","turnoverRate":0.009708,"peRate":70.141496,"marketCap":44142373723.5,"floatMarketCap":39946575171,"timestamp":1786737599999,"nameCN":"避孕概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":3,"down":1,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1132499934","title":"Dare Bioscience 宣佈完成600萬美元註冊直接發行，按納斯達克規則市價定價","url":"https://stock-news.laohu8.com/highlight/detail?id=1132499934","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132499934?lang=zh_tw&edition=fundamental","pubTime":"2026-08-15 00:46","pubTimestamp":1786725969,"startTime":"0","endTime":"0","summary":"Dare Bioscience（股票代码：DARE）今日正式宣告，其此前披露的600万美元注册直接发行已顺利完成定价。此次发行严格遵循纳斯达克市场规则，采用市价发行机制。这笔资金将用于公司运营与研发推进，标志着公司在资本市场再获关键助力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DARE","BK4584","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133368521","title":"Dare Bioscience 發布2026年第二季度財報：多產品女性健康戰略推進，商業拐點凸顯","url":"https://stock-news.laohu8.com/highlight/detail?id=1133368521","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133368521?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 04:02","pubTimestamp":1786651343,"startTime":"0","endTime":"0","summary":"Dare Bioscience（股票代码：DARE）近日公布了2026年第二季度业绩报告。报告显示，随着公司多产品女性健康战略的持续深入，其商业运营已迎来关键转折点。在本次财报中，公司不仅披露了当季财务数据，更着重强调了这一战略转型的积极信号。从产品线布局到市场拓展，种种迹象表明，这家专注于女性健康的生物科技企业正加速驶入商业化快车道。尽管具体数字尚待进一步分析，但“商业拐点”这一表述本身已足以引发市场对其未来增长潜力的无限遐想。在竞争激烈的女性健康赛道，Dare Bioscience 正凭借其多元化的产品组合，试图开辟出一条差异化的发展路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DARE","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105142491","title":"Femasys Inc：Maxim Group 將目標價從30美元下調至10美元，以反映1比20的反向股票分割","url":"https://stock-news.laohu8.com/highlight/detail?id=1105142491","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105142491?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 22:25","pubTimestamp":1786631147,"startTime":"0","endTime":"0","summary":"Femasys Inc 近期迎来重大调整。Maxim Group 已将其目标股价从30美元大幅下调至10美元。这一变动，旨在精准反映公司实施的1比20反向股票拆分动作。此举意味着，每20股现有股票将合并为1股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4082","BK4584","FEMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113446157","title":"Veru Inc. 公布2026財年第三季度財務業績及2B期Plateau臨床試驗進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1113446157","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113446157?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 18:32","pubTimestamp":1786357972,"startTime":"0","endTime":"0","summary":"Veru Inc. 近日发布了其2026财年第三季度的财务报告，同时更新了备受关注的2B期Plateau临床试验的最新进展。这家生物制药公司正稳步推进其核心研发项目，而市场投资者也对其关键疗法管线的未来走向投以密切关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERU","BK4007","BK4183","BK4557","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657655274","title":"特瓦公司試圖向陪審團隱瞞與以色列的關聯，並援引加沙戰爭作為理由","url":"https://stock-news.laohu8.com/highlight/detail?id=2657655274","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657655274?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 00:19","pubTimestamp":1786033193,"startTime":"0","endTime":"0","summary":"特瓦公司试图向陪审团隐瞒与以色列的关联，并援引加沙战争作为理由特瓦指出，自加沙战争以来，对以色列的敌意日益加剧这家制药公司表示，公司起源与本案无关关于定价指控的庭审定于下月举行Mike Scarcella路透华盛顿8月6日-特瓦制药公司已请求美国法官禁止保险公司胡玛纳在一场重大的药品价格垄断审判中向陪审团透露其是一家以色列公司，理由是公众对加沙战争  的强烈看法可能会影响审判程序，并影响该公司获得公正审理的能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL4S44321U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348723411.USD","LU0256863811.USD","LU0211331839.USD","LU1983260115.SGD","LU1093756168.USD","TEVA","BK4588","BK4007","SG9999014005.SGD","LU0266013472.USD","BK4596","SG9999014021.USD","HUM","LU0238689110.USD","BK4557","LU0417517546.SGD","LU0170899867.USD","BK4559","LU0320765489.SGD","BK4533","LU1093756325.SGD","LU0390134368.USD","BK4154","BK4585","SG9999014013.SGD","LU1983299246.USD","BK4566","LU0070302665.USD","LU2324357040.USD","FXH","BK4584","LU0208291251.USD","IHF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194932615","title":"Veru 宣佈關鍵專利獲批：Enobosarm 聯合司美格魯肽用於高質量減重","url":"https://stock-news.laohu8.com/highlight/detail?id=1194932615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194932615?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 20:31","pubTimestamp":1785846686,"startTime":"0","endTime":"0","summary":"Veru Inc. 日前正式宣布，已收到美国专利商标局关于其关键用途方法的授权通知。这项专利核心聚焦于Enobosarm与司美格鲁肽的联合应用，旨在实现“高质量减重”——即在减少脂肪的同时，保留肌肉质量。此次专利授权，无疑为Veru在代谢疾病治疗领域的创新布局提供了强有力的法律支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4007","VERU","BK4183","BK4584"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}